654 related articles for article (PubMed ID: 28472477)
1. Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Petta S; Valenti L; Svegliati-Baroni G; Ruscica M; Pipitone RM; Dongiovanni P; Rychlicki C; Ferri N; Cammà C; Fracanzani AL; Pierantonelli I; Di Marco V; Meroni M; Giordano D; Grimaudo S; Maggioni M; Cabibi D; Fargion S; Craxì A
J Clin Endocrinol Metab; 2017 Aug; 102(8):2660-2669. PubMed ID: 28472477
[TBL] [Abstract][Full Text] [Related]
2. A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR.
Metwally M; Bayoumi A; Romero-Gomez M; Thabet K; John M; Adams LA; Huo X; Aller R; García-Monzón C; Teresa Arias-Loste M; Bugianesi E; Miele L; Gallego-Durán R; Fischer J; Berg T; Liddle C; Qiao L; George J; Eslam M
J Hepatol; 2019 Mar; 70(3):494-500. PubMed ID: 30389552
[TBL] [Abstract][Full Text] [Related]
3. Fibronectin Type III Domain-Containing 5 Attenuates Liver Fibrosis Via Inhibition of Hepatic Stellate Cell Activation.
Zhou B; Ling L; Zhang F; Liu TY; Zhou H; Qi XH; Chen Q; Li YH; Kang YM; Zhu GQ
Cell Physiol Biochem; 2018; 48(1):227-236. PubMed ID: 30007970
[TBL] [Abstract][Full Text] [Related]
4. NAD
Li DJ; Sun SJ; Fu JT; Ouyang SX; Zhao QJ; Su L; Ji QX; Sun DY; Zhu JH; Zhang GY; Ma JW; Lan XT; Zhao Y; Tong J; Li GQ; Shen FM; Wang P
Theranostics; 2021; 11(9):4381-4402. PubMed ID: 33754067
[No Abstract] [Full Text] [Related]
5. Therapeutic role of FNDC5/irisin in attenuating liver fibrosis via inhibiting release of hepatic stellate cell-derived exosomes.
Liao X; Luo Y; Gu F; Song W; Nie X; Yang Q
Hepatol Int; 2023 Dec; 17(6):1659-1671. PubMed ID: 37046114
[TBL] [Abstract][Full Text] [Related]
6.
Gao F; Zheng KI; Zhu PW; Li YY; Ma HL; Li G; Tang LJ; Rios RS; Liu WY; Pan XY; Targher G; Byrne CD; Chen YP; Zheng MH
Br J Nutr; 2021 Sep; 126(6):813-824. PubMed ID: 33198849
[TBL] [Abstract][Full Text] [Related]
7. Hepatic FNDC5 is a potential local protective factor against Non-Alcoholic Fatty Liver.
Canivet CM; Bonnafous S; Rousseau D; Leclere PS; Lacas-Gervais S; Patouraux S; Sans A; Luci C; Bailly-Maitre B; Iannelli A; Tran A; Anty R; Gual P
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165705. PubMed ID: 32001301
[TBL] [Abstract][Full Text] [Related]
8. MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease.
Petta S; Valenti L; Marra F; Grimaudo S; Tripodo C; Bugianesi E; Cammà C; Cappon A; Di Marco V; Di Maira G; Dongiovanni P; Rametta R; Gulino A; Mozzi E; Orlando E; Maggioni M; Pipitone RM; Fargion S; Craxì A
J Hepatol; 2016 Mar; 64(3):682-90. PubMed ID: 26596542
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
[TBL] [Abstract][Full Text] [Related]
10. Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.
Cai CX; Buddha H; Castelino-Prabhu S; Zhang Z; Britton RS; Bacon BR; Neuschwander-Tetri BA
Dig Dis Sci; 2017 Apr; 62(4):968-978. PubMed ID: 28194671
[TBL] [Abstract][Full Text] [Related]
11. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
12. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
[TBL] [Abstract][Full Text] [Related]
13. Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis.
Pohl R; Haberl EM; Rein-Fischboeck L; Zimny S; Neumann M; Aslanidis C; Schacherer D; Krautbauer S; Eisinger K; Weiss TS; Buechler C
Eur J Clin Invest; 2017 Jan; 47(1):7-18. PubMed ID: 27797398
[TBL] [Abstract][Full Text] [Related]
14. mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance.
Meroni M; Longo M; Erconi V; Valenti L; Gatti S; Fracanzani AL; Dongiovanni P
Nutrients; 2019 Oct; 11(11):. PubMed ID: 31671785
[TBL] [Abstract][Full Text] [Related]
15. CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading.
Chu X; Jin Q; Chen H; Wood GC; Petrick A; Strodel W; Gabrielsen J; Benotti P; Mirshahi T; Carey DJ; Still CD; DiStefano JK; Gerhard GS
J Transl Med; 2018 Apr; 16(1):108. PubMed ID: 29690903
[TBL] [Abstract][Full Text] [Related]
16. Extracellular vesicles derived from fat-laden hepatocytes undergoing chemical hypoxia promote a pro-fibrotic phenotype in hepatic stellate cells.
Hernández A; Reyes D; Geng Y; Arab JP; Cabrera D; Sepulveda R; Solis N; Buist-Homan M; Arrese M; Moshage H
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165857. PubMed ID: 32512191
[TBL] [Abstract][Full Text] [Related]
17. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease.
Liang D; Chen H; Zhao L; Zhang W; Hu J; Liu Z; Zhong P; Wang W; Wang J; Liang G
Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):133-142. PubMed ID: 29038049
[TBL] [Abstract][Full Text] [Related]
19. Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH).
Hartimath SV; Boominathan R; Soh V; Cheng P; Deng X; Chong YC; Yong FF; Tan PW; Han W; Robins EG; Goggi JL
Contrast Media Mol Imaging; 2019; 2019():6298128. PubMed ID: 31866798
[TBL] [Abstract][Full Text] [Related]
20. Loss of SREBP-1c ameliorates iron-induced liver fibrosis by decreasing lipocalin-2.
Lee EH; Lee JH; Kim DY; Lee YS; Jo Y; Dao T; Kim KE; Song DK; Seo JH; Seo YK; Seong JK; Moon C; Han E; Kim MK; Ryu S; Shin M; Roh GS; Jung HR; Osborne TF; Ryu D; Jeon TI; Im SS
Exp Mol Med; 2024 Apr; 56(4):1001-1012. PubMed ID: 38622198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
